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inappropriate selection of patients for randomization is the
fact that mortality in the conventional arm was 1/42¼ 2.38%,
which is at least 7 times lower than that in the general
population of hemodialysis (HD) patients in the United States.
Many patients in the control group performed more frequent
dialysis sessions and those in the more frequent group
performed less frequent dialyses. The ultimate conclusion that
was reached was that the frequent nocturnal dialysis study
group had improvement in ‘‘control of hyperphosphatemia
and hypertension but no beneﬁt among other main secondary
outcomes’’. Improvement of left ventricular mass was rejected
as insigniﬁcant on the basis of a P-value of 0.09, which means a
chance difference probability of 1 in 11 instead of 1 in 20. We
wonder whether the Student’s paired t-test, if performed in
the patients in the ‘frequent group’, would show that a
decrease of left ventricular mass from an average of 141 to 132
was in fact statistically signiﬁcant. In all, this study committed
a type II statistical error because of the evidently small
number and inappropriate selection of subjects. On the basis
of this study it absolutely cannot be accepted that frequent
nocturnal HD is not better than conventional thrice-weekly
HD. Interestingly, the front page of Kidney International
egregiously highlights the rather misperceived notion that
frequent nocturnal HD is of no beneﬁt!
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The Authors Reply: Drs Misra and Twardowski1 claim that
subjects in the Frequent Hemodialysis Network (FHN)
Nocturnal Trial2 were inappropriately selected. All rando-
mized subjects in the Nocturnal Trial had stage V chronic
kidney disease and o20% of subjects had a urea clearance
43ml/min. Although the mortality rate in both the FHN
Daily and Nocturnal Trials was lower than that seen in the
general hemodialysis population, this observation is common
to randomized clinical trials and is likely due to the exclusion
of subjects with a limited life expectancy who would not be
inﬂuenced by the intervention. Less than 10% of subjects in
the control arm performed dialysis X4 times per week
(Figure 2)2 and 72% of subjects in the more frequent arm had
X4.8 treatments per week (Table 2).2 In addition, the separa-
tion in the weekly dose of dialysis between arms was robust
(total weekly standard Kt/Vurea of 5.03±1.23 vs. 2.91±0.86,
Po0.001). While our ﬁndings for left ventricular mass (LVM)
did not achieve statistical signiﬁcance, the mean change and
95% conﬁdence intervals for LVM were not materially
different from the results of the FHN Daily Trial.3 We
provided several possible explanations for the non-signiﬁcant
effect of more frequent dialysis on LVM in our discussion,2 as
did Davenport in his commentary.4 Finally, the summary
statement on the front cover was not written by the authors
but was provided by the Kidney International staff. We did
not conclude that there is no beneﬁt of nocturnal dialysis
on LVM.
1. Misra M, Twardowski ZJ. Benefits of frequent nocturnal home
hemodialysis. Kidney Int 2012; 82: 114–115.
2. Rocco MV, Lockridge RS, Beck GJ et al. The effects of frequent nocturnal
home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial.
Kidney Int 2011; 80: 1080–1091.
3. Chertow GM, Levin NW, Beck GJ et al. In-center hemodialysis six
times per week versus three times per week. N Engl J Med 2010; 363:
2287–2300.
4. Davenport A. How best to improve survival in hemodialysis patients:
solute clearance or volume control? Kidney Int 2011; 80: 1018–1020.
Michael V. Rocco1 and Alan S. Kliger2
1Section of Nephrology, Wake Forest University School of Medicine, Winston-
Salem, North Carolina, USA and 2Hospital of Saint Raphael, Yale University,
New Haven, Connecticut, USA
Correspondence: Michael V. Rocco, Section of Nephrology, Wake Forest
University School of Medicine, Medical Center Boulevard, Winston-Salem,
North Carolina 27157-1053, USA. E-mail: mrocco@wakehealth.edu
Kidney International (2012) 82, 115; doi:10.1038/ki.2012.96
Implausible similarities in patient
characteristics between two
randomized controlled studies: a
coincidence is unlikely
To the Editor: We have read the interesting article of the
randomized controlled trial (RCT) by Goraya et al.1 showing
that 30-day dietary acid reduction with an aggressive intake of
fruits and vegetables (FþV) has a renoprotective effect for stage
2 chronic kidney disease (CKD). Despite the small sample
size, it clearly demonstrated the efﬁcacy of FþV by both
clinical and experimental surrogate markers. Its effect is
almost the same with that of sodium bicarbonate, which had
already been shown to attenuate the rate of decline of the
glomerular ﬁltration rate in a 5-year RCT by the same group
of this study.2 Thus, FþV without the increase in sodium
intake may be more favorable than sodium bicarbonate for
early CKD patients.
However, the characteristics of the participants with
stage 2 CKD between these two RCTs are implausibly
similar (Table 1). These similarities are impossible for two
separate RCTs with at least a 5-year interval. Even if these
studies were conducted in parallel without a detailed
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